Exploring Affibody Molecules as Vehicles for Molecular Radiotherapy of HER2- expressing Malignancies: ABY-025 for Patient Selection & ABY-271 for Radioligand Therapy
Time: 12:00 pm
day: Day 2 - P&T Track AM
Details:
- Selecting patients by immunohistochemistry has limitations and image-guided decisions have recently proven superior
- Using the PET tracer ABY-025 todemonstrated correlation with improved treatment response prediction and can be translated therapeutically using linker technology for improved kinetics
- ABY-271 is a candidate in late preclinical development for molecular radiotherapy of HER2 expressing cancers
